NLS Pharmaceutics AG and Kadimastem Ltd. have announced the granting of a patent by the Hong Kong Intellectual Property Department for Kadimastem's proprietary cell selection and enrichment technology. This technology is used in the development of IsletRx, a stem cell-derived therapy candidate aimed at treating insulin-dependent diabetes. The newly granted patent in Hong Kong complements previously secured patents in Europe, the United States, and India, further strengthening the global protection for IsletRx. This milestone supports the long-term strategy for advancing Kadimastem's diabetes program and underscores the potential of IsletRx as a curative cell therapy for diabetes patients worldwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-084281), on September 04, 2025, and is solely responsible for the information contained therein.